These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18948370)

  • 1. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
    Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
    Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
    Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL
    J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
    Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
    Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
    Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
    Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
    Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
    Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
    Baden J; Adams S; Astacio T; Jones J; Markiewicz J; Painter J; Trust C; Wang Y; Green G
    J Urol; 2011 Nov; 186(5):2101-6. PubMed ID: 21944123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
    JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
    Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
    Urologiia; 2015; (5):46-50. PubMed ID: 26859937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.